To date, there is no study available of the relation between chronic use of ACE inhibitors and ARB, considered separately, and mortality in hospitalized COVID-19 patients that includes sufficient patients in the older age group, and that accounts for concomitant cardiovascular therapies or comorbid conditions. The gene discussed is ACE; the disease is COVID-19.